Onconetix Seeks Shareholder Approval for Another Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Onconetix, Inc. is seeking stockholder approval for a reverse stock split, with a ratio between 1-for-2 and 1-for-50, to maintain its Nasdaq listing amidst ongoing compliance challenges and a mandatory panel monitor.

check_boxKey Events

• Proposal for Reverse Stock Split Authority

  Stockholders will vote on granting the Board authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-50.

• Nasdaq Listing Compliance

  The primary reason for the proposed split is to maintain compliance with Nasdaq's minimum bid price rule, which is crucial for the company's market presence.

• Recent Reverse Split and Panel Monitor

  The company previously executed a 1-for-85 reverse stock split in June 2025 and is currently under a mandatory Nasdaq panel monitor until July 2026, which removes the standard grace period for future bid price non-compliance.

• Risks of Delisting

  Failure to maintain Nasdaq listing could lead to trading on over-the-counter markets, significantly reducing liquidity, investor interest, and the company's ability to raise capital.

auto_awesomeAnalysis

Onconetix is proposing a reverse stock split to address potential future non-compliance with Nasdaq's minimum bid price rule. This action follows a previous 1-for-85 reverse split in June 2025 and the company's current status under a mandatory Nasdaq panel monitor until July 2026. The monitor means any future bid price non-compliance will result in an immediate delisting determination without the standard grace period. The repeated need for reverse splits highlights significant challenges in maintaining a sustainable stock price and Nasdaq listing, which is critical for a micro-cap company's access to capital and market visibility. This proactive measure underscores the precariousness of its listing status and the underlying operational or financial issues preventing organic price appreciation.